STATE MEDICAID P&T COMMITTEE MEETING

THURSDAY, March 18, 2010
7:00 a.m. to 8:30 a.m.
Cannon Health Building
Room 114

MINUTES

Committee Members Present:

Ellie Brownstein, M.D.
Kort Delost, R.Ph.
Karen Gunning, PharmD.
Duane Parke, R.Ph.
Beth Johnson, R.Ph.
Michael Flynn, M.D.
Brandon Jennings, PharmD.
Raymond Ward, M.D.

Board Members Excused:

Dept. of Health/Div. of Health Care Financing Staff Present:

Jennifer Zeleny, CPhT, MPH
Tim Morley, R.Ph.
Lisa Hulbert, R.Ph.

University of Utah Drug Information Center Staff Present:

Dave Peterson, PharmD.

Other Individuals Present:

Sabrina Aery, BMS
Derek Butters, Novo Nordisk
Kali Williams, U of U
Emily Goldman, U of U
Stacie Stromness, U of U
D. Crawford, Novo Nordisk
Sergey Zhuplatov, BMS
Brett Brewer, EMD Serono
Alan Bailey, Pfizer
Sean Leavitt, U of U
Arash Mohiyer, U of U

Meeting conducted by: Karen Gunning, Co-Chairperson.

---

1. Minutes for February 2010 were reviewed, corrected, and approved. Dr. Ward moved to approve the minutes. Dr. Flynn seconded the motion. The motion passed with unanimous votes by Brandon Jennings, Dr. Flynn, Karen Gunning, Dr. Ward, Duane Parke, and Beth Johnson.

2. DUR Board Update: Lisa Hulbert addressed the Committee. Some legislation passed during the last legislative session that allows the DUR Board to post the agenda 14 days in advance, wait only 30 days before placing a PA, and discuss cost. The DUR Board also considered evidence for 17p, and changed the time-frame for initiation of therapy. The Vivitrol PA had the requirement for liver function testing removed, and a new PA was placed on Zovirax ointment. The DUR Board will not be meeting in April 2010.

3. Legislative Update: Duane Parke addressed the Committee. The Legislature did not allow the P&T Committee to address mental health drugs this year. He presented savings reports from the PDL project. The savings is put back into the rates for physicians.

4. DPP4 Inhibitors: Dr. Dave Peterson of the University of Utah Drug Information Service addressed the Committee and presented evidence on the drug class.

Dr. Sergey Zhuplatov from Bristol Myers Squibb addressed the Committee on the benefits of saxagliptin marketed worldwide as Onglyza.

Karen Gunning asked if there is any information on the effectiveness of DPP4's in relation to the duration of the disease. Dr. Zhuplatov stated that these data were not available yet. The studies contained a mixture of newly diagnosed and long-duration diabetics. Mostly they were long-duration diabetics.

Dr. Flynn stated that he had received a letter from a drug company with a new warning on a drug. Dr. Zhuplatov stated that there have been no warnings issued and no post-launch events with Onglyza. Karen stated she recalled seeing warnings about drugs in a different class.

Duane asked about dose decreases because of kidney status or drug-drug interactions. Dr. Zhuplatov stated that the therapeutic dosage was 5mg. Strong inhibitors of P-450 increase exposure to the drug, and a reduction of dosage is recommended for this situation. Also, there is a one-step dose reduction to 2.5mg for moderate kidney impairment.

The Committee asked about the beta cell preservation with this class versus sulfonoureas. Dr. Peterson stated that this is an area of interest, because theoretically these drugs may preserve beta cells. However, there is no evidence available on this yet.

Karen asked if there is any comparison on adding one of these drugs versus switching to insulin. There is no evidence on this.

Karen asked if there was any reason for the hypersensitivity increase compared to placebo. Dr. Peterson stated that there are warnings for both drugs, but no explanation as to why this would occur.

Karen asked Lisa if these drugs currently require a clinical PA. They do not require a clinical PA. The physicians on the Committee stated that there have been times where these drugs are desirable due to contraindications with other classes of drugs.

Dr. Ward stated that he did not feel there was any evidence showing that one or the other drugs in this class were superior to each other.

Dr. Ward moved that he finds both drugs equally safe and efficacious. Dr.

Flynn seconded the motion. The motion passed with unanimous votes by Dr. Brownstein, Beth Johnson, Kort DeLost, Dr. Flynn, Karen Gunning, Brandon Jennings, Duane Parke, and Dr. Ward.

Duane announced that the SSDC purchasing group would be meeting to review bids in either June or July, and that he would announce cancellations of the P&T Committee meeting for that month as he found out exact dates.

Next Meeting Set for Thursday, April 15, 2010
Meeting Adjourned.

Minutes prepared by Jennifer Zeleny